Julie
is a real patient
with RA, performing
an everyday activity...
Welcome to ACTEMRA/RoACTEMRA World
This website is intended as an extensive resource site for healthcare professionals outside the US with an interest in rheumatoid arthritis (RA) and its treatment with ACTEMRA®/RoACTEMRA® (tocilizumab), a first-in-class agent with a novel mechanism of action that targets the interleukin-6 (IL-6) receptor.
The product is known as RoACTEMRA in the EU and Mexico and as ACTEMRA in other countries.
This site contains, amongst other things, information on the mechanism of action of ACTEMRA/RoACTEMRA, guides to dosing and administration, and efficacy and safety data from key Phase III clinical trials. There is also a useful resource section containing a range of downloadable materials on RA and ACTEMRA/RoACTEMRA.
This website is based on the RoACTEMRA label in the EU and became live early in 2009, coinciding with the approval of ACTEMRA/RoACTEMRA in Europe. In addition to the facilities already available, there are many others planned or under construction. Please keep coming back to the site for the latest information on ACTEMRA/RoACTEMRA and RA.
Now approved for sJIA
ACTEMRA/RoACTEMRA is the first and only approved treatment for systemic juvenile idiopathic arthritis (sJIA). This section provides a variety of information and materials for both patients and healthcare professionals relating to the use of ACTEMRA/RoACTEMRA in the management of sJIA. More...
About ACTEMRA
This section contains detailed scientific and medical information on ACTEMRA/RoACTEMRA, including the mechanism of action, dosage and administration details, and safety and efficacy information from key clinical trials. More...
Resources
This section provides a wealth of useful information and practical items for both patients and healthcare professionals relating to the management of rheumatoid arthritis (RA) and the use of ACTEMRA/RoACTEMRA. More...